SEK 2.54
(-5.22%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 36.42 Million SEK | -40.38% |
2022 | 61.09 Million SEK | 345.88% |
2021 | 13.7 Million SEK | 32.52% |
2020 | 10.34 Million SEK | -2.08% |
2019 | 10.56 Million SEK | -9.05% |
2018 | 11.61 Million SEK | 103.42% |
2017 | 5.7 Million SEK | 57.47% |
2016 | 3.62 Million SEK | 109.73% |
2015 | 1.72 Million SEK | 54.67% |
2014 | 1.11 Million SEK | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 27.45 Million SEK | -11.16% |
2024 Q1 | 30.89 Million SEK | -15.18% |
2023 Q2 | 50.34 Million SEK | -8.68% |
2023 Q4 | 36.42 Million SEK | -11.11% |
2023 FY | 36.42 Million SEK | -40.38% |
2023 Q1 | 55.13 Million SEK | -9.76% |
2023 Q3 | 40.98 Million SEK | -18.6% |
2022 Q2 | 24 Million SEK | 64.52% |
2022 Q3 | 19.1 Million SEK | -20.44% |
2022 FY | 61.09 Million SEK | 345.88% |
2022 Q4 | 61.09 Million SEK | 219.87% |
2022 Q1 | 14.59 Million SEK | 6.49% |
2021 Q3 | 10.5 Million SEK | -65.93% |
2021 Q1 | 9.66 Million SEK | -6.52% |
2021 Q2 | 30.84 Million SEK | 219.06% |
2021 FY | 13.7 Million SEK | 32.52% |
2021 Q4 | 13.7 Million SEK | 30.42% |
2020 Q4 | 10.34 Million SEK | -4.07% |
2020 FY | 10.34 Million SEK | -2.08% |
2020 Q2 | 10.31 Million SEK | -7.35% |
2020 Q1 | 11.13 Million SEK | 5.4% |
2020 Q3 | 10.77 Million SEK | 4.53% |
2019 Q2 | 8.56 Million SEK | 2.64% |
2019 Q3 | 8.42 Million SEK | -1.66% |
2019 FY | 10.56 Million SEK | -9.05% |
2019 Q4 | 10.56 Million SEK | 25.37% |
2019 Q1 | 8.34 Million SEK | -28.13% |
2018 Q3 | 5.32 Million SEK | -10.6% |
2018 FY | 11.61 Million SEK | 103.42% |
2018 Q1 | 5.26 Million SEK | -7.74% |
2018 Q2 | 5.95 Million SEK | 13.06% |
2018 Q4 | 11.61 Million SEK | 118.13% |
2017 Q4 | 5.7 Million SEK | 15.78% |
2017 FY | 5.7 Million SEK | 57.47% |
2017 Q3 | 4.93 Million SEK | 1.61% |
2017 Q2 | 4.85 Million SEK | 10.65% |
2017 Q1 | 4.38 Million SEK | 20.97% |
2016 FY | 3.62 Million SEK | 109.73% |
2016 Q1 | 2.07 Million SEK | 19.89% |
2016 Q2 | 4.12 Million SEK | 99.18% |
2016 Q4 | 3.62 Million SEK | 30.48% |
2016 Q3 | 2.77 Million SEK | -32.69% |
2015 FY | 1.72 Million SEK | 54.67% |
2015 Q3 | 796 Thousand SEK | -63.17% |
2015 Q4 | 1.72 Million SEK | 117.13% |
2015 Q2 | 2.16 Million SEK | 0.0% |
2015 Q1 | - SEK | -100.0% |
2014 FY | 1.11 Million SEK | 0.0% |
2014 Q4 | 1.11 Million SEK | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
AcuCort AB | 10.97 Million SEK | -231.909% |
AlzeCure Pharma AB (publ) | 8.22 Million SEK | -342.774% |
BioGaia AB (publ) | 302.84 Million SEK | 87.972% |
Enzymatica AB (publ) | 49.3 Million SEK | 26.115% |
Enorama Pharma AB (publ) | 14.84 Million SEK | -145.349% |
Gabather AB (publ) | 6.87 Million SEK | -429.616% |
Klaria Pharma Holding AB (publ.) | 31.98 Million SEK | -13.884% |
Moberg Pharma AB (publ) | 24 Million SEK | -51.735% |
Newbury Pharmaceuticals AB (publ) | 38.95 Million SEK | 6.487% |
ODI Pharma AB | 10.05 Million SEK | -262.181% |
Orexo AB (publ) | 727.7 Million SEK | 94.994% |
Probi AB (publ) | 181.31 Million SEK | 79.91% |
Swedencare AB (publ) | 2.31 Billion SEK | 98.427% |
Swedish Orphan Biovitrum AB (publ) | 40.16 Billion SEK | 99.909% |
Toleranzia AB | 6.9 Million SEK | -427.24% |
Vivesto AB | 30.45 Million SEK | -19.621% |